Disc Medicine, Inc. (NASDAQ:IRON) Director Kevin Bitterman Sells 664 Shares

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) Director Kevin Bitterman sold 664 shares of Disc Medicine stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $61.13, for a total transaction of $40,590.32. Following the sale, the director owned 676,839 shares in the company, valued at approximately $41,375,168.07. This represents a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kevin Bitterman also recently made the following trade(s):

• On Thursday, July 24th, Kevin Bitterman sold 13,033 shares of Disc Medicine stock. The stock was sold at an average price of $61.17, for a total value of $797,228.61.
• On Wednesday, July 23rd, Kevin Bitterman sold 29,837 shares of Disc Medicine stock. The shares were sold at an average price of $60.97, for a total value of $1,819,161.89.

Disc Medicine Stock Up 0.0%

NASDAQ IRON traded up $0.03 on Friday, hitting $60.61. 224,396 shares of the company were exchanged, compared to its average volume of 378,410. The company has a current ratio of 37.65, a quick ratio of 37.65 and a debt-to-equity ratio of 0.04. The company has a market cap of $2.10 billion, a PE ratio of -15.46 and a beta of 0.76. The stock has a fifty day moving average of $52.69 and a 200-day moving average of $51.41. Disc Medicine, Inc. has a 12 month low of $30.82 and a 12 month high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03). As a group, analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in IRON. Arizona State Retirement System increased its holdings in shares of Disc Medicine by 12.5% during the first quarter. Arizona State Retirement System now owns 5,315 shares of the company's stock valued at $264,000 after acquiring an additional 590 shares in the last quarter. Amalgamated Bank grew its position in Disc Medicine by 38.6% in the 1st quarter. Amalgamated Bank now owns 787 shares of the company's stock valued at $39,000 after purchasing an additional 219 shares during the period. Renaissance Technologies LLC acquired a new stake in Disc Medicine in the 4th quarter valued at $5,479,000. Rhumbline Advisers increased its stake in Disc Medicine by 10.7% during the 1st quarter. Rhumbline Advisers now owns 32,144 shares of the company's stock valued at $1,596,000 after purchasing an additional 3,108 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in Disc Medicine by 5,092.5% during the first quarter. GAMMA Investing LLC now owns 12,410 shares of the company's stock worth $616,000 after buying an additional 12,171 shares during the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IRON has been the topic of a number of recent analyst reports. Wedbush reaffirmed an "outperform" rating and issued a $90.00 price objective on shares of Disc Medicine in a research note on Monday, July 21st. BMO Capital Markets raised their price target on shares of Disc Medicine from $112.00 to $120.00 and gave the stock an "outperform" rating in a report on Monday, May 12th. Raymond James Financial initiated coverage on shares of Disc Medicine in a research note on Wednesday, June 11th. They issued a "strong-buy" rating and a $89.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $118.00 target price on shares of Disc Medicine in a research note on Thursday, July 3rd. Finally, Truist Financial started coverage on shares of Disc Medicine in a report on Monday, July 21st. They issued a "buy" rating and a $86.00 target price on the stock. Eleven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $95.73.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.